SynthesisInternational journal of medical sciences2026

Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.

Jian Lu et al.PubMed ↗Full text ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with lower glycemic control

−15%−27% to −2%

Bigger than 1 in 10 for glycemic control

As reported

OR 0.85, 95% CI 0.73–0.98

Correlation, not cause

Went with lower glycemic control

−34%−56% to −2%

Bigger than 3 in 10 for glycemic control

As reported

OR 0.66, 95% CI 0.44–0.98

Correlation, not cause

Went with lower glycemic control

−36%−50% to −18%

Bigger than 3 in 10 for glycemic control

As reported

OR 0.64, 95% CI 0.50–0.82

+2 more in the walkthrough ↓

Five numbers in the abstract

the abstract, start to end

… associated with reduced risks of CAD (OR 0.85, 95% CI 0.73-0.98), HF (OR 0.66, 95% CI 0.44-0.98), and MetS (OR 0.64, 95% CI 0.50-0.82).

… with a higher risk of MetS (OR 1.07, 95% CI 1.02-1.13), and thiazolidinediones (TZDs) with an increased risk of HF (OR 1.12, 95% CI 1.05-1.20).

← favours treatmentfavours comparator →

could be chance

Glycemic control

OR 0.850.73–0.98

Glycemic control

OR 0.660.44–0.98

Glycemic control

OR 0.640.50–0.82

Glycemic control

OR 1.071.02–1.13

Glycemic control

OR 1.121.05–1.20

SGLT2 inhibitorsInsulinGlycemic control

1 / 3

Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.

What moved togetherboth groups pooled, not the treatment’s effect

Went with lower glycemic control

Went with lower glycemic control

Went with lower glycemic control

Five numbers in the abstract

Where each one falls

Where it lands on the map

Not cited yet